NASDAQ:RSLS - Reshape Lifesciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0670 -0.01 (-12.99 %) (As of 08/20/2018 04:54 AM ET)Previous Close$0.0670Today's Range$0.0650 - $0.077452-Week Range$0.05 - $39.00Volume8.62 million shsAverage Volume1.44 million shsMarket Capitalization$610,000.00P/E Ratio0.00Dividend YieldN/ABeta2.2 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Its product portfolio also comprises ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California. Receive RSLS News and Ratings via Email Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:RSLS CUSIP29365M20 Webwww.enteromedics.com Phone949-429-6680 Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.29 Price-To-Earnings Trailing P/E Ratio0.00 Forward P/E Ratio-0.03 P/E GrowthN/A Sales & Book Value Annual Sales$1.29 million Price / Sales0.33 Cash FlowN/A Price / CashN/A Book Value$38.22 per share Price / Book0.00 Profitability EPS (Most Recent Fiscal Year)($47.68) Net Income$-33,810,000.00 Net Margins-1,715.25% Return on Equity-69.19% Return on Assets-60.38% Miscellaneous Employees83 Outstanding Shares6,380,000Market Cap$610,000.00 Reshape Lifesciences (NASDAQ:RSLS) Frequently Asked Questions What is Reshape Lifesciences' stock symbol? Reshape Lifesciences trades on the NASDAQ under the ticker symbol "RSLS." When did Reshape Lifesciences' stock split? How did Reshape Lifesciences' stock split work? Shares of Reshape Lifesciences reverse split before market open on Monday, June 4th 2018. The 1-15 reverse split was announced on Friday, June 1st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 1st 2018. An investor that had 100 shares of Reshape Lifesciences stock prior to the reverse split would have 7 shares after the split. How were Reshape Lifesciences' earnings last quarter? Reshape Lifesciences Inc (NASDAQ:RSLS) posted its quarterly earnings data on Tuesday, August, 14th. The medical device company reported ($4.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.79) by $3.01. The medical device company had revenue of $0.65 million for the quarter. Reshape Lifesciences had a negative net margin of 1,715.25% and a negative return on equity of 69.19%. View Reshape Lifesciences' Earnings History. When is Reshape Lifesciences' next earnings date? Reshape Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Reshape Lifesciences. What is the consensus analysts' recommendation for Reshape Lifesciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reshape Lifesciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Reshape Lifesciences. Are investors shorting Reshape Lifesciences? Reshape Lifesciences saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 381,259 shares, a decline of 28.7% from the July 13th total of 534,928 shares. Based on an average daily trading volume, of 259,696 shares, the short-interest ratio is presently 1.5 days. Approximately 8.8% of the company's stock are sold short. View Reshape Lifesciences' Current Options Chain. Who are some of Reshape Lifesciences' key competitors? Some companies that are related to Reshape Lifesciences include Escalon Medical (ESMC), Trimedyne (TMED), SpectraScience (SCIE), Guided Therapeutics (GTHP), 21st North (ULGX), Newcardio (NWCI), IMRIS (IMRSQ), Echo Therapeutics (ECTE) and Magna-Lab (MAGAA). Who are Reshape Lifesciences' key executives? Reshape Lifesciences' management team includes the folowing people: Mr. Dan W. Gladney, Chairman, Pres & CEO (Age 65)Mr. Scott P. Youngstrom, CFO, Sr. VP of Fin. & Sec. (Age 58)Mr. Naqeeb A. Ansari, VP of Worldwide Sales (Age 57)Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 57) Has Reshape Lifesciences been receiving favorable news coverage? Media headlines about RSLS stock have trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Reshape Lifesciences earned a daily sentiment score of 0.20 on Accern's scale. They also assigned headlines about the medical device company an impact score of 46.66 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Reshape Lifesciences. Who are Reshape Lifesciences' major shareholders? Reshape Lifesciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include International Biotechnology Trust PLC (0.82%). View Institutional Ownership Trends for Reshape Lifesciences. Which major investors are selling Reshape Lifesciences stock? RSLS stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC. View Insider Buying and Selling for Reshape Lifesciences. How do I buy shares of Reshape Lifesciences? Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Reshape Lifesciences' stock price today? One share of RSLS stock can currently be purchased for approximately $0.0670. How big of a company is Reshape Lifesciences? Reshape Lifesciences has a market capitalization of $610,000.00 and generates $1.29 million in revenue each year. The medical device company earns $-33,810,000.00 in net income (profit) each year or ($47.68) on an earnings per share basis. Reshape Lifesciences employs 83 workers across the globe. How can I contact Reshape Lifesciences? Reshape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected] MarketBeat Community Rating for Reshape Lifesciences (NASDAQ RSLS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 234 (Vote Outperform)Underperform Votes: 191 (Vote Underperform)Total Votes: 425MarketBeat's community ratings are surveys of what our community members think about Reshape Lifesciences and other stocks. Vote "Outperform" if you believe RSLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?